GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
- Proof-of-concept trial to evaluate safety and biomarkers of cancer cell mobilization in patients with hormone receptor positive metastatic breast cancer
GlycoMimeticsdrug candidate targets tumor and bone marrow microenvironments
The trial’s Co-Principal Investigators are
"Dr. Sipkins’ work suggests that both E-selectin and CXCR4 mediate key
mechanisms that promote progression and migration of circulating cancer
cells to protective niches. Importantly, her work reveals a potentially
exciting approach to molecularly excise disseminated breast cancer cells
with GMI-1359, which was rationally designed to inhibit both of these
targets," said John Magnani, Ph.D., Senior Vice President and Chief
Scientific Officer at
“Our preclinical research in mice suggests that targeting E-selectin and CXCR4 with a single agent may potentially improve treatment of patients at risk of metastasis to bone, or whose tumors might have already spread,” said Dr. Sipkins.
“If ultimately shown safe and effective in clinical trials, this agent could represent a potentially novel approach to treating metastatic cancer, and we’re pleased to begin exploring the use of this investigational therapy in individuals with metastatic cancer,” added Dr. Marcom.
GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules involved in tumor trafficking and metastatic spread. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as AML and multiple myeloma or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer. GMI-1359 has completed a Phase 1 clinical trial in healthy volunteers.
GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
This press release contains forward-looking statements regarding the
clinical development and regulatory pathway and potential benefits and
impact of the company’s drug candidates. Actual results may differ
materially from those in these forward-looking statements. For a further
description of the risks associated with these statements, as well as
other risks facing
1 Price et. al. Science Translational Medicine, (2016) 8:340.